Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Figure 3

Expression of candidate target mRNAs. (a) Transcriptional expressions of PTEN, BIM, p21, and E2F1 were analyzed with real-time RT-PCR in CD4⁺ T cells from untreated and natalizumab treated patients (untreated: 𝑛=8; Nat. treated: 𝑛=10) (bars represent median with interquartile range) and (b) in freshly isolated CD4⁺ T cells from HVs transiently transfected by electroporation (EP) with 1 μM of miR-17 synthetic inhibitor (ImiR-17) or vehicle control (mock) ((b) middle and right panels). Analysis of miR-17 transcriptional expression ((b) left panel). Values represent mean with SEM for 8 independent experiments. Relative expression levels are depicted. Unpaired two-tailed 𝑡-test was used.^∗∗∗𝑃<0.001;^∗∗𝑃<0.01;^∗𝑃<0.05; n.s.: not significant.

(a)

(b)